Eli Lilly’s mirikizumab triumphs in Phase 3 Crohn’s disease study
Eli Lilly and Company (NYSE: LLY), a pharmaceutical leader, unveiled that mirikizumab, its cutting-edge interleukin-23p19 antagonist, has demonstrated its prowess against placebo in the critical VIVID-1 Phase 3 trial. The study, crucial for those with moderately to severely active Crohn’s disease, has established mirikizumab as a beacon of hope in the treatment landscape. Striking Results […]